This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Merrimack Pharmaceuticals, Inc. announced that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva?? (erlotinib) in patients with non- small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
We care about your feedback. Let us know how we can improve your CancerCompass experience.